Susan Tarry, MD
Urology · Baltimore, MDNPI 1770798019
Payments from drug & device makers
Across 239 payments — averaging $32.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$1K
- Medtronic$887
- Sumitomo Pharma America, Inc.$883
- Boston Scientific$502
- Urovant Sciences Inc$447
- Endo Pharmaceuticals Inc.$425
- plus $4K from 34 others
What the payments were for
- Speaking & faculty fees$1121%
- Travel & lodging$2563%
- Food & beverage$7,38694%
- Education$1101%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 13 | $1,003 |
| Medtronic(2 entities) | 24 | $887 |
| Sumitomo Pharma America, Inc. | 43 | $883 |
| Boston Scientific | 8 | $502 |
| Urovant Sciences Inc | 29 | $447 |
| Endo Pharmaceuticals Inc. | 16 | $425 |
| Cook Medical LLC | 4 | $404 |
| Laborie Medical Technologies Corp. | 3 | $383 |
| Bayer | 9 | $275 |
| Johnson & Johnson(2 entities) | 8 | $240 |
| Astellas Pharma US Inc | 11 | $232 |
| AbbVie | 6 | $212 |
| Progenics Pharmaceuticals, Inc. | 5 | $198 |
| Myriad Genetic Laboratories, Inc. | 6 | $184 |
| Calyxo, Inc. | 1 | $148 |
| Teleflex LLC | 1 | $139 |
| Tolmar Pharmaceuticals, Inc. | 5 | $123 |
| Merck | 6 | $122 |
| Renovia Inc | 2 | $103 |
| Novartis | 4 | $98 |
| Ferring Pharmaceuticals Inc. | 5 | $98 |
| Caldera Medical, Inc | 1 | $80 |
| Myovant Sciences Inc. | 3 | $78 |
| Urogen Pharma, Inc. | 1 | $76 |
| Endo USA, Inc. | 3 | $65 |
| Blue Earth Diagnostics | 3 | $65 |
| AstraZeneca | 2 | $62 |
| Olympus America Inc. | 1 | $50 |
| Antares Pharma, Inc. | 2 | $42 |
| Convatec Inc. | 2 | $39 |
| 180 Medical, Inc. | 2 | $29 |
| Caris MPI, Inc. | 1 | $26 |
| Palette Life Sciences, Inc. | 1 | $24 |
| Tolmar, Inc. | 1 | $22 |
| Amgen | 1 | $21 |
| Mimedx Group, Inc. | 1 | $21 |
| Clarus Therapeutics Inc. | 2 | $21 |
| Foundation Medicine, Inc. | 1 | $13 |
| Acerus Pharmaceuticals Corporation | 1 | $13 |
| Clovis Oncology, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$280
- INTERSTIM$275
- Optilume BPH Drug Coated Balloon Catheter$260
- Cook Medical Urology$256
- GEMTESA$247
- Saffron$174
- rezum Generator$172
- CVAC Aspiration System$148
- UroLift$139
- Porges Coloplast$136
- AMS 700 CXR RTE KIT$132
- Xofigo$124
- Cook Medical Perc Sets$119
- XIAFLEX$118
- BOTOX$115
- PYLARIFY$114
- Prolaris$113
- ORGOVYX$112
How this compares
$7,864 in reported general payments places this provider in the 60th percentile of 274 urology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 18 | $259,470 |
| GemtesaVibegron | 77 | $71,515 |
| MyrbetriqMirabegron | 54 | $47,625 |
| Methenamine Hippurate | 132 | $14,449 |
| Tadalafil | 11 | $3,041 |
| Estradiol | 40 | $2,958 |
| Tamsulosin Hcl | 139 | $2,253 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 118 | $1,781 |
| Potassium Citrate ErPotassium Citrate | 14 | $1,393 |
| Finasteride | 48 | $1,115 |
| Oxybutynin Chloride | 67 | $1,007 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 20 | $889 |
| Oxybutynin Chloride ErOxybutynin Chloride | 45 | $857 |
| Ciprofloxacin Hcl | 52 | $625 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 11 | $482 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $232 | $307,09672 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $883 | $71,51577 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 274 urology providers in Maryland.
Other urology in Baltimore
- Ronald TutroneBaltimore$18.1M
- Mohamad AllafBaltimore$7.1M
- Max KatesBaltimore$1000K
- Benjamin LowentrittBaltimore$994K
- Kenneth LangerBaltimore$610K
- Arvin GeorgeBaltimore$518K
- Mohummad SiddiquiBaltimore$321K
- Christian PavlovichBaltimore$271K
- Arthur BurnettBaltimore$235K
- Brian MatlagaBaltimore$170K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.